Abiopharma

DEFA14A (Additional Proxy Soliciting Materials (definitive)) SEC Filing

8-K (Current report filing) SEC Filing

Sellas Life Sciences - SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta

QHSLab, Inc. (OTCQB:USAQ) Completes $500K Private Placement, Enters 2026 With Clean Capital Structure

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Genmab Portfolio Prioritization Update

Inovio - FDA Accepts for Review INOVIOs BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

FDA Accepts for Review INOVIOs BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)